Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

C4 Therapeutics (CCCC) EBIAT (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of EBIAT data on record, last reported at -$20.5 million in Q4 2025.

  • For Q4 2025, EBIAT rose 40.72% year-over-year to -$20.5 million; the TTM value through Dec 2025 reached -$105.0 million, changed 0.29%, while the annual FY2025 figure was -$105.0 million, 0.29% changed from the prior year.
  • EBIAT reached -$20.5 million in Q4 2025 per CCCC's latest filing, up from -$32.2 million in the prior quarter.
  • Across five years, EBIAT topped out at -$15.7 million in Q4 2021 and bottomed at -$37.2 million in Q4 2022.
  • Average EBIAT over 5 years is -$27.7 million, with a median of -$27.2 million recorded in 2022.
  • Peak YoY movement for EBIAT: crashed 137.48% in 2022, then soared 50.68% in 2024.
  • A 5-year view of EBIAT shows it stood at -$15.7 million in 2021, then plummeted by 137.48% to -$37.2 million in 2022, then grew by 6.54% to -$34.8 million in 2023, then rose by 0.57% to -$34.6 million in 2024, then skyrocketed by 40.72% to -$20.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were -$20.5 million in Q4 2025, -$32.2 million in Q3 2025, and -$26.0 million in Q2 2025.